The ROCKET-AF (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) study on more than 14,000 patients with nonvalvular atrial fibrillation included 1,878 patients from Latin America in the intention-to-treat population.23 This evidence concerns the gene F10 and Stroke.